Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


Scil Technology Initiates Research into Cartilage Repair Using a Cartilage-Specific Growth Factor

Cartilage in joints can be damaged in traumatic injury or through the processes of osteoarthritis. In either case, it can result in excruciating pain as bones rub against each other without the cushioning effect of the cartilage. Current therapies focus on the symptomatic treatment with pain killers or NSAIDs or ultimately on surgical replacement with synthetic prosthetic joints. Scil plans to develop treatments or implants that will actually encourage the cartilage to re-grow.
The basis for Scil’s approach to the regeneration of cartilage is the recombinant growth factor rhMIA / CD-RAP (or recombinant human cartilage derived retinoic acid sensitive protein, a growth regulatory protein precursor). This represents a substantially novel molecule for cartilage regeneration. It is highly specific for cartilage tissue and has been shown to play a crucial role during cartilage formation in embryonic development and in adult animals. Moreover, rhMIA stimulates the synthesis of cartilage matrix as demonstrated with cartilage cells from osteoarthritic patients. , , These properties make rhMIA a highly promising candidate for cartilage regeneration.
Dr Irina Staatz-Granzer, Managing Director of Scil Technology, commented:
“Up until now, Scil Technology has been known as a company focussed on the regeneration of bones in the first place. This new programme, focused on cartilage repair, will allow us to develop new therapies for osteochondral defects resulting from traumatic joint injury or from osteoarthritis. These are indications of very high unmet clinical need.”

– ends –

About Scil Technology GmbH
Scil Technology is a private biopharmaceutical development company focused on dental and orthopaedic tissue regeneration with a particular emphasis on bone and cartilage repair. The Company’s lead therapeutic candidates are based on recombinant, highly specific human growth factors. These are combined with biodegradable biomaterials to generate local application forms. Scil Technology’s pipeline for dentistry includes products that are targeted at periodontal disease, dental implantology and maxillofacial surgery. Orthopaedic products are developed for spinal fusion, traumatic lesions of bone and cartilage tissue and osteoarthritis. Scil Technology has emerged from the Scil Group and is located in the biotechnology cluster in Martinsried, Germany.
For more information please visit:

Publisher Contact Information:

Scil Technology GmbH
+49 (0)89 85651824

Company profile of Scil Technology GmbH
Past press releases of Scil Technology GmbH.


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Nov 25€24.0MInternet commerce
Jan 17N/AIT services
Jan 17€7.4MInternet commerce
Jan 16€100.0MConsumer electronics
Jan 16€23.0MBiotechnology
Jan 15€1.2MEnergy related
Jan 15€28.0MKnowledge management

For information on Europe's most extensive database on technology funding click here!


Press Releases

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.